• Natera announced three published, peer-reviewed studies evaluating its Signatera test in head and neck cancer.
• Post-surgery testing identified patients likely to benefit from adjuvant chemotherapy; patients testing negative showed no improvement with chemotherapy.
• Surveillance testing detected recurrence earlier than imaging across HPV-positive and HPV-negative disease, outperforming clinical risk factors in predicting progression.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Natera Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20261104932386) on November 04, 2026, and is solely responsible for the information contained therein.